The Atypical HUS Foundation

aHUS Global Survey for Patents & Caregivers - Launched Rare Disease Day 2016

     The aHUS Alliance, an umbrella group of 15 nations with aHUS patient groups, launched a worldwide survey of aHUS patients and caregivers to mark Rare Disease Day 2016 (29 February).  A similar effort was conducted in partnership with RareConnect in 2014, with 214 respondents from 17 nations and responding to outreach in 6 different languages.  The 2014 poll included questions on common themes familiar to patients with rare diseases and echoing broadly on Rare Disease Day:  barriers to diagnosis, access to treatment, availability of genetic testing, need for increased research efforts, participation in registries and clinical trials, and better/more information about their rare disease.

      Rare Disease Day, created in 2008 by EURORDIS, helps the world to better understand the challenges and support needs faced by rare disease patients and their families.  This special day serves to underscore the need to share knowledge about all rare disease issues and information, and also champions the call for development of new research for diagnostics and treatment.  Rare Disease Day historically has included momentum for advancement of national plans and policies for rare diseases in a number of countries as well.  To honor the intent of the day with an action of collaborative advocacy, advocates within the aHUS Alliance chose Rare Disease Day to launch its 2016 aHUS global poll.

     In 2014, the global aHUS survey brought some interesting facts to light and we expect similar value in the 2016 survey results.  After only two days, the 2016 aHUS global poll garnered responses from 34 aHUS patients and caregivers in 8 nations, expanding in the first week for a total of 78 survey respondents from 10 countries.  This year’s poll will be open during all of March 2016, with survey results to expected to be available in both global data and country-specific formats.

 From the aHUS Alliance commentary on 2014 aHUS poll results:

Of the 214 aHUS patients included in the Survey almost two thirds (64%) were reported as being female with just 36% being male (Q2). There appeared to be no gender difference in respondents up to 18 years (41 to 41) but it is in the adult group that females vastly outnumber males (95 to 37). Only in the preteens group do boys slightly outnumber girls (36 to 32). Children up to 10 years of age were the largest reported group (28%) and the next largest group (21%) were aged 30 to 40 years (Q3). The average age of all respondents was 27 years.

The majority of patients (54%) reported that they had their first severe episode of aHUS before their 21st birthday and for most of those it was even before they were 10 years old. Very few became ill (4%) after their 50th birthday so most of the remaining patients became ill in early adult hood to middle age (Q5). The average time respondents have been living with the illness is 8 years, making 19, the average age of onset.

To read the rest of the aHUS Alliance 2014 poll commentary, click HERE.

To access 2014 RareConnect aHUS global poll charts and graphs, click HERE.

To view Dr. Tim Goodship’s webinar on interpreting 2014 RareConnect aHUS global. click HERE to view Dr. Goodship’s webinar. (with links to slides and poll assets)

 

     So why launch an aHUS global poll in 2016?  Certain questions and topics have repeatedly appeared within patient communities, aHUS social media outlets, and within meetings such as the aHUS global conference of nations in London 28 June 2015.  Atypical HUS patient groups within the aHUS Alliance network to connect information, opportunities, and stakeholders within the aHUS arena.  In the orphan drug arena, the landscape is rapidly changing.  Though people with atypical HUS face the threat of a chronic disease with life-threatening health crises, most nations have limited access to full treatment options.  Clinical trials, diagnosis advancements, research updates, and development of complement inhibitors all have tremendous impact on patient lives.  But is there a way to provide researchers, clinicians, and industry insight into how best to interface with patients and patient organizations to the benefit of all stakeholders?  Is there a way to involve aHUS patients and caregivers worldwide as valued partners in patient care, to include even those isolated patients currently not represent by an aHUS patient organization?  Can patient experiences regarding aHUS diagnosis and treatment issues provide valuable insights for policy makers and the healthcare community?

      Members within the aHUS Alliance think meaningful information from the 2016 aHUS global poll can provide researchers, clinical trial investigators and industry a better perspective of how to reach physicians and their patients.  The survey also was designed to help patient groups better understand the needs of their members and to explore the differences in care, diagnosis and treatment access around the world. We believe the data from the 2016 aHUS global poll additionally will provide aHUS patient organizations data to present to their government’s policy makers, healthcare industry, and Health Ministers concerning options in their nations for continuation or expansion of patient care and treatment options. 

     We encourage all individuals – all nations – all aHUS patient organization to encourage aHUS patients and caregivers around the world to participate in the 2016 aHUS global survey.

 

Click HERE to view a blog regarding 2016 possibilities for potential new aHUS treatments.

Click HERE for the 2016 aHUS global survey.

Survey Results will be posted on www.ahusallianceaction.org   

E: Info@aHUSallianceaction.org           Twitter:  @aHUSallianceact

Blog about the survey, from patient organization Atypical HUS India

March 16, 2016, UPDATE:   Click the link to read the

 Mid-Point Survey Blog at RareConnect 

Views: 140

Comment

You need to be a member of The Atypical HUS Foundation to add comments!

Join The Atypical HUS Foundation

IN REGARD TO MEMBERSHIP REQUESTS

To ensure proper processing of your membership, please make sure to set your email filters to accept emails, from info@atypicalhus.org.

The Atypical HUS Foundation is an all-volunteer organization. Please allow at least 72 hours for an email response confirming your membership request.  If you do not receive an email, please check your spam folder or email directly to info@atypicalhus.org

Membership is open to patients, family, friends, caregivers research and medical personnel.

WELCOME - JOIN US!

The Atypical HUS Foundation encourages patients and investigators to share information and explore options/resources as we work together to gain insight into this rare complement disorder. By increasing contact opportunities with researchers and medical personnel interested in helping the aHUS community, our stories foster a better understanding of atypical hemolytic uremic syndrome.

Sharing information, inspiration and support for one another, we seek to gather together people and knowledge as we strive to improve the lives of patients and families dealing with a diagnosis of aHUS.


NEW DIAGNOSIS OF aHUS?
Be proactive! Get the medical basics of aHUS, what lab values to monitor, and areas of concern...check out the "aHUS Bootcamp" and "About aHUS" tabs at the top of this page!
If your doctor has never treated a case of aHUS, please print out our 'Doc to Doc Registry' and ask him/her to contact a physician versed in the complexities of aHUS and new options for 2011 genetic testing and treatment.

************************

NOTE: Our 'Send a Message" function on each Member's page allows for private discussion of personal content. As with any social network, be cautious about giving personal contact information (home email info, phone number) until you have an established relationship with another person, organization, or associated website.

 

Did you know...

CFH (Serum Complement Factor H) is a regulatory protein. The secreted protein product of CFH consists of 20 repetitive units named "short consensus repeats" or SCRs (each approximately 60 amino acids). In patients with aHUS the last 5 "pearls" in the twenty pearl strand protein, SCR16 - SCR20, should bind to protect cells but do not- they are defective in one or more of the last 5 SCR locations. If they cannot bind or stick to the kidney to protect that tissue, the platelets clump into clots that affect the glomeruli of the kidney -potentially causing acute renal failure.
  
• • • • • • • • • • • •
  
It is estimated that there are about 2 cases of aHUS in the U.S. per 1,000,000 of population, and about 60% of aHUS patients are diagnosed as children. The condition is potentially life threatening, and either can be chronic or can recur at intervals.
  
more factoids...

Help us fight the battle

Your donation of $295.for an aHUS pearl bracelet will directly fund research to help aHUSpatient and their families. Each bracelet has an appraised value of $925, and is offered with your gift of $295. Note:  For shipping outside the USA, please add $25. to cover international shipping costs.

(Note: Bracelets do not qualify as tax deductible donations under IRS regulations.)

Normally, aHUS pearl bracelets to be made-to-order and as such expect a 4 to 6 week window before your custom bracelet is shipped.  In a rush?  Contact info@atypicalhus.org with your request and details.

 

 Donations of a specific dollar amount are welcome-every dollar will help aHUS research efforts supported by The Atypical HUS Foundation at www.atypicalhus.org.


Donations may be made via credit card or Paypal. If you prefer, checks made payable to The Atypical HUS Foundation may be mailed to:

The Atypical HUS Foundation
C/O Deborah Lewis
PO Box 333
Barnhart, MO 63012


For pearl bracelet orders, please allow extra time for processing checks. Questions about aHUS donations? Please email info@atypicalhus.org

Badge

Loading…

© 2017   Created by Deborah Lewis.   Powered by

Badges  |  Report an Issue  |  Terms of Service